Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Abbott GmbH & Co. KG
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
The objectives of the Phase 1 portion of the study include: ● Safety assessment ● Dose limiting toxicity (DLT) determination ● Maximum tolerated dose (MTD) determination ● Pharmacokinetic profile eval...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients with Diabetic Peripheral Neuropathy
To assess the effect of single dose of ABT-639 on spontaneous activity in peripheral C nociceptors measured through microneurography in subjects with painful diabetic peripheral neuropathy (DPN) compa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A randomized, open-label, study of lopinavir/ritonavir 400/100 mg tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily versus lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily in antiretroviral-naive, HIV-1 infected subjects
- to compare the safety and tollerability of lopinavir/ritonavir (LPV/r) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) with a nucleoside-sparing regimen consisting of LPV/r + raltegravir (RL...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease
The primary efficacy measure will be assessment of cognitive functioning and memory impairment using the ADAS-cog; the primary efficacy variable will be the change from baseline to final evaluation on...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)
To evaluate the overall survival (OS) of oral linifanib given as monotherapy daily (QD) compared to sorafenib given twice daily (BID) as standard of care in subjects with advanced or metastatic HCC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Study of Two Different Adalimumab Formulations in Adults with Rheumatoid Arthritis
Compare the injection site related pain profile of two different formulations of Humira immediately after injection.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 co-administered with Ribavirin (RBV) in people that have been previously treated for Hepatitis C Virus (HCV). "Experimental" means that they have not been approved by any regulatory agency for sale to the public
The primary objectives of this study are to compare the percentage of subjects achieving SVR12 (HCV RNA < lower limit of quantification [LLOQ] 12 weeks following treatment) of 12 weeks of treatment wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 in people with Hepatitis C Virus. "Experimental" means that they have not been approved by any regulatory agency for sale to the public. Estudio para evaluar la seguridad y el efecto de tres fármacos experimentales ABT-450, ABT-267 y ABT-333 en pacientes con el virus de la Hepatitis C. ?Experimental? significa que no han sido aprobados por ninguna agencia reguladora para su venta al público
Assess the safety of all treatment regimens and the percentage of subjects achieving 24-week sustained virologic response (SVR24) (HCV RNA < LLOD at post-treatment Week 24) following treatment with 3 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
A Multicenter, Randomized, Double-blind, Placebo controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis
To assess the efficacy and safety of adalimumab for the induction and maintenance of clinical remission in subjects with moderately to severely active ulcerative colitis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Abbott GmbH & Co. KG
MAJ Il y a 4 ans
Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo diseñado para demostrar la eficacia y la seguridad del adalimumab como tratamiento de mantenimiento en sujetos adultos que precisan corticosteroides en dosis altas por uveítis intermedia, uveítis posterior o panuveítis no infecciosa activa
El objetivo de este estudio es evaluar la eficacia y la seguridad de una dosis inicial de 80 mg de adalimumab seguida de una dosis de 40 mg administrada cada dos semanas por vía subcutánea (s.c.) a pa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
Suivant